Multiple Myeloma

Latest News

February 22nd 2023

Discussing Consent for Supportive Care Agents with Patients with Multiple Myeloma

By Ajai Chari, MD, Annel Urena, Kiah Purcell

Nurse Practitioner Kiah Purcell explains how she discusses supportive care agents with patients receiving a BCMA-targeting bispecific for multiple myeloma in case a patient experiences cytokine release syndrome.

Latest Videos

Donna Catamero, ANP-BC, OCN, CCRC, an expert on multiple myeloma

MonumenTAL-1: Talquetamab in Relapsed/Refractory MM

Clinical Pearls for Community Physicians Treating Patients With RRMM With CAR T-Cell Therapy

Ciltacabtagene Autoleucel in Patients With MM: Efficacy and Safety Data From CARTITUDE-1

A panel of 4 experts on multiple myeloma seated at a long table

Multiple Myeloma: Treatment Considerations and Role of MRD

Consolidation and Maintenance Therapy Considerations in Multiple Myeloma

Saad Usmani, MD, MBA, FACP, an expert on multiple myeloma

Overview of Relapsed/Refractory Multiple Myeloma

How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?

Navigating CAR-T Therapy in RRMM: Patient Counsel and Managing AEs

Available Options for CAR T-Cell Therapy in Patients With RRMM

Patient Case Presentation: A 62-Year-Old Woman With High-Risk Multiple Myeloma

CME Content

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Iowa Oncology Society

Marla D. Lipsyc-Sharf, MD; Sheila Donnelly, MD

Video

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Christine M. Lovly, MD, PhD, FASCO; Xiuning Le, MD, PhD; Hossein Borghaei, DO, MS; Lyudmila Bazhenova, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Texas Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Parth Khade, MD

Video

22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Omid Hamid, MD; Sapna Patel, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Marla D. Lipsyc-Sharf, MD; Yan Ji, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Kimberly Ku, MD

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Video

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

Video

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Audio

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Video

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

(CME Track) Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck - Post-CRT Decisions in the Locally Advanced Setting

Quynh-Thu Le, MD, FACR, FASTRO; Vlad C. Sandulache, MD, PhD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Rocky Mountain Oncology Society

Seth A. Wander, MD, PhD; Kara M. Schenk, MD

Virtual Event

Oncology Town Hall - Translating the Latest Updates Into the Care of Patients With AML in Community Practices

April 9, 2026

In-Person + Virtual Event

11th Annual School of Gastrointestinal Oncology® (SOGO®)

April 11, 2026

In-Person + Virtual Event

Tumor Board: Clinical Integration of Molecular Profiling in Glioma - Transforming the Use of Targeted Therapy

April 20, 2026

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Video

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Video

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Audio

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Audio

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

More News

Selecting and Sequencing Bispecifics and CAR-T Therapies in R/R MM

ByBeth Faiman, PhD, MSN, APN-BC,Sandra Mazzoni, MD,Jack Khouri, MD,Louis Williams, MD

February 16th 2023

A review of novel treatment modalities for relapsed/refractory multiple myeloma, with a focus on selecting and sequencing bispecific antibodies and CAR T-cell therapies.

Patient Case 3: Relapsed/Refractory Multiple Myeloma

ByBeth Faiman, PhD, MSN, APN-BC,Sandra Mazzoni, MD,Jack Khouri, MD,Louis Williams, MD

February 16th 2023

Expert panelists center discussion on a final patient case to review the identification and management of relapsed/refractory multiple myeloma.

$Sikander Ailawadhi, MD, discussed the safety and efficacy of talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma following a readout of the phase 1/2 MonumenTAL-1 trial.$

MonumenTAL-1 trial Shows Promise With Talquetamab in R/R Myeloma

ByKristie L. Kahl

February 15th 2023

Sikander Ailawadhi, MD, discussed the safety and efficacy of talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma following a readout of the phase 1/2 MonumenTAL-1 trial.

Bispecifics in the Treatment of Multiple Myeloma: Teclistamab

ByMelissa Alsina, MD,Rachid Baz, MD,Brandon Blue, MD,Ken Shain, MD, PhD

February 15th 2023

Panelists review data from the MajesTEC-1 clinical trial and elucidate the role of teclistamab therapy in patients with relapsed/refractory multiple myeloma.

Sequencing Therapies in Relapsed/Refractory Multiple Myeloma

ByMelissa Alsina, MD,Rachid Baz, MD,Brandon Blue, MD,Ken Shain, MD, PhD

February 15th 2023

Shared insight on the value of using effective regimens upfront and optimal sequencing throughout several lines of therapy in multiple myeloma.

$The investigational CAR T-cell therapy equecabtagene autoleucel receives fast track and regenerative medicine advanced therapy designations for managing relapsed or refractory multiple myeloma.$

FDA Grants Fast Track and RMAT Designations to CAR T Product for R/R Myeloma

ByRuss Conroy

February 15th 2023

The investigational CAR T-cell therapy equecabtagene autoleucel receives fast track and regenerative medicine advanced therapy designations for managing relapsed or refractory multiple myeloma.

Step-Up Doses in Patients Receiving Teclistamab for Multiple Myeloma

ByAjai Chari, MD,Annel Urena,Kiah Purcell

February 15th 2023

A review of the process of “step-up” doses in teclistamab therapy for multiple myeloma and their use.

Process of Administering Teclistamab and Other Bispecific Agents

ByAjai Chari, MD,Annel Urena,Kiah Purcell

February 15th 2023

A review of the process of giving a patient a dose of teclistamab from start to finish.

$Survival appears to be significantly improved when idecabtagene vicleucel is given vs standard of care in relapsed/refractory multiple myeloma.$

Updated Data from KarMMA-3 Show Improved PFS in Relapsed/Refractory Myeloma

ByAriana Pelosci

February 14th 2023

Survival appears to be significantly improved when idecabtagene vicleucel is given vs standard of care in relapsed/refractory multiple myeloma.

Review of Patient Subgroups in Transplant-Ineligible NDMM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

February 13th 2023

Oncology expert panelists review patient subgroup analyses for MAIA and SWOG0777 studies, investigating treatments for transplant-ineligible patients with newly diagnosed multiple myeloma.

Clinical Trials in Transplant-Ineligible NDMM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

February 13th 2023

Expert panelists review clinical data from studies investigating treatment regimens for patients with NDMM that are transplant-ineligible.

Non–BCMA-Targeting Bispecific Antibodies in R/R MM

BySagar Lonial, MD, FACP, FASCO,Sandy Wong, MD,Caitlin Costello, MD,Timothy Schmidt, MD,Samuel M. Rubinstein, MD

February 13th 2023

A brief review of non–BCMA-targeted bispecific antibodies under investigation in patients with relapsed/refractory multiple myeloma.

BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

BySagar Lonial, MD, FACP, FASCO,Sandy Wong, MD,Caitlin Costello, MD,Timothy Schmidt, MD,Samuel M. Rubinstein, MD

February 13th 2023

Expert perspectives on recent clinical data on BCMA-targeted bispecific antibody therapy in patients with relapsed/refractory multiple myeloma.

Treatment Strategies for Patients With Transplant-Ineligible NDMM

ByBeth Faiman, PhD, MSN, APN-BC,Sandra Mazzoni, MD,Jack Khouri, MD,Louis Williams, MD

February 10th 2023

Expert perspectives on selection of induction therapy for patients with transplant-ineligible newly diagnosed multiple myeloma.

Patient Case 2: Transplant-Ineligible Newly Diagnosed Multiple Myeloma

ByBeth Faiman, PhD, MSN, APN-BC,Sandra Mazzoni, MD,Jack Khouri, MD,Louis Williams, MD

February 10th 2023

Panelists move on to review a patient case of transplant-ineligible newly diagnosed multiple myeloma and highlight clinical workup strategies.

Relapsed/Refractory Multiple Myeloma: Overview of Treatment Options

ByMelissa Alsina, MD,Rachid Baz, MD,Brandon Blue, MD,Ken Shain, MD, PhD

February 8th 2023

Switching their focus to the relapsed/refractory setting, experts from the Moffit Cancer Center consider second-line treatment options for patients with multiple myeloma.

Patient Profile 2: Transplant-Ineligible Newly Diagnosed Multiple Myeloma

ByMelissa Alsina, MD,Rachid Baz, MD,Brandon Blue, MD,Ken Shain, MD, PhD

February 8th 2023

Expert perspectives on a patient profile of transplant-ineligible multiple myeloma, with considerations for treatment selection and defining transplant ineligibility.

The Role of Teclistamab in Multiple Myeloma

ByAjai Chari, MD,Annel Urena,Kiah Purcell

February 8th 2023

Dr Ajai Chari explains the mechanism of action of BCMA-targeting bispecifics and the role of teclistamab in multiple myeloma treatment.

Patient Experience With Treatment for Multiple Myeloma and Clinical Trial Participation

ByAjai Chari, MD,Annel Urena,Kiah Purcell

February 8th 2023

Anne-Marie Jacob describes her early treatment regimen for multiple myeloma and her experience with clinical trial enrollment.

Induction Therapy in Transplant-Ineligible NDMM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

February 6th 2023

A panel of expert oncologists consider treatment options for patients with NDMM that are transplant-ineligible.

Role of Transplant and Induction Therapies in NDMM

ByRobert Z. Orlowski, MD, PhD,Amrita Y. Krishnan, MD,C. Ola Landgren, MD, PhD,Ajay K. Nooka, MD,Cesar Rodriguez, MD

February 6th 2023

Expert perspectives on the role of transplants and induction therapy in patients with newly diagnosed multiple myeloma (NDMM).

Selecting Treatment Regimens for Multiple Myeloma at First Relapse

BySagar Lonial, MD, FACP, FASCO,Sandy Wong, MD,Caitlin Costello, MD,Timothy Schmidt, MD,Samuel M. Rubinstein, MD

February 6th 2023

Turning to the last module, expert panelists discuss the treatment armamentarium for patients experiencing early relapse in multiple myeloma.

Choosing the Right Treatment for Patients With Transplant Ineligible MM

BySagar Lonial, MD, FACP, FASCO,Sandy Wong, MD,Caitlin Costello, MD,Timothy Schmidt, MD,Samuel M. Rubinstein, MD

February 6th 2023

Patient and disease factors that help to select best first-line therapy in the setting of transplant-ineligible multiple myeloma.

Optimal Selection of Therapy for Patients With Transplant-Eligible NDMM

ByBeth Faiman, PhD, MSN, APN-BC,Sandra Mazzoni, MD,Jack Khouri, MD,Louis Williams, MD

February 3rd 2023

A focused discussion on navigating the treatment armamentarium for patients with transplant-eligible newly diagnosed multiple myeloma.

Patient Case 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma

ByBeth Faiman, PhD, MSN, APN-BC,Sandra Mazzoni, MD,Jack Khouri, MD,Louis Williams, MD

February 3rd 2023

Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists consider optimal workup and management strategies.